Second-line treatments for Advanced Hepatocellular Carcinoma: A Systematic Review and Bayesian Network Meta-analysis

[1]  M. Kudo,et al.  Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib , 2020, JAMA oncology.

[2]  H. Yoshiji,et al.  A randomized, double‐blind, placebo‐controlled, phase 3 study of tivantinib in Japanese patients with MET‐high hepatocellular carcinoma , 2020, Cancer science.

[3]  L. Rimassa,et al.  Navigating the new landscape of second‐line treatment in advanced hepatocellular carcinoma , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[4]  Yulei N. Wang,et al.  Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. , 2020, The New England journal of medicine.

[5]  M. Kudo,et al.  Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. , 2020, Journal of hepatology.

[6]  M. Kudo,et al.  Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  V. Longo,et al.  Role of BRAF in Hepatocellular Carcinoma: A Rationale for Future Targeted Cancer Therapies , 2019, Medicina.

[8]  Ming Luo,et al.  Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma , 2019, Journal of Experimental & Clinical Cancer Research.

[9]  M. Cescon,et al.  Carcinogenesis and Metastasis in Liver: Cell Physiological Basis , 2019, Cancers.

[10]  V. Longo,et al.  Emerging Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma , 2019, Medicina.

[11]  V. Longo,et al.  Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib , 2019, Medicina.

[12]  E. El Rassy,et al.  Second-line Treatments of Advanced Hepatocellular Carcinoma: Systematic Review and Network Meta-Analysis of Randomized Controlled Trials , 2019, Journal of clinical gastroenterology.

[13]  M. Kudo,et al.  Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. , 2019, The Lancet. Oncology.

[14]  J. Bruix,et al.  Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial. , 2018, Journal of hepatology.

[15]  Gisela Schwab,et al.  Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma , 2018, The New England journal of medicine.

[16]  M. Kudo,et al.  Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. , 2018, The Lancet. Oncology.

[17]  F. Izzo,et al.  Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  R. Gelber,et al.  Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis. , 2018, The Lancet. Oncology.

[19]  C. Porta,et al.  Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. , 2018, The Lancet. Oncology.

[20]  M. Kudo,et al.  Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial , 2018, The Lancet.

[21]  M. Kudo,et al.  Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial , 2017, The Lancet.

[22]  M. Kudo,et al.  S-1 versus placebo in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE): a randomised, double-blind, multicentre, phase 3 trial. , 2017, The lancet. Gastroenterology & hepatology.

[23]  J. Rowe,et al.  Review of hepatocellular carcinoma: Epidemiology, etiology, and carcinogenesis , 2017, Journal of carcinogenesis.

[24]  M. Lai,et al.  Prescription Patterns of Sorafenib and Outcomes of Patients with Advanced Hepatocellular Carcinoma: A National Population Study. , 2017, Anticancer research.

[25]  Masatoshi Kudo,et al.  Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial , 2017, The Lancet.

[26]  M. Kudo,et al.  Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma. , 2016, Journal of hepatology.

[27]  D. Chakrabarti,et al.  Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  Gerta Rücker,et al.  Ranking treatments in frequentist network meta-analysis works without resampling methods , 2015, BMC Medical Research Methodology.

[29]  Joon-Oh Park,et al.  Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. , 2015, The Lancet. Oncology.

[30]  V. Saraswat,et al.  Treatment algorithms for managing hepatocellular carcinoma. , 2014, Journal of clinical and experimental hepatology.

[31]  M. Kudo,et al.  Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. , 2014, JAMA.

[32]  M. Kudo,et al.  Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  S. Paggi,et al.  Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.

[34]  Dieter Häussinger,et al.  Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.

[35]  A. Gasbarrini,et al.  Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. , 2013, The Lancet. Oncology.

[36]  J. Bruix,et al.  Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification , 1999, Seminars in liver disease.